These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 11908711

  • 1. Current management of polycythemia vera.
    Tefferi A.
    Leuk Lymphoma; 2002 Jan; 43(1):1-7. PubMed ID: 11908711
    [Abstract] [Full Text] [Related]

  • 2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 3. Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea.
    Cacciola E, Cacciola RR, Guglielmo P, Stagno F, Giustolisi R.
    Haematologica; 1999 Aug; 84(8):755-6. PubMed ID: 10457418
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T, Finazzi G.
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Björkholm M, Hultcrantz M, Derolf ÅR.
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
    [Abstract] [Full Text] [Related]

  • 10. [Metamorphosis of chronic myeloproliferative diseases].
    Butoianu E, Nicoară S, Coliţă A, Ursea C, Berceanu S.
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983 Jun; 35(3):223-32. PubMed ID: 6140716
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
    Sirhan S, Busque L, Foltz L, Grewal K, Hamm C, Laferriere N, Laneuville P, Leber B, Liew E, Olney HJ, Prchal J, Porwit A, Gupta V.
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
    [Abstract] [Full Text] [Related]

  • 13. How to Treat Essential Thrombocythemia and Polycythemia Vera.
    Besses C, Alvarez-Larrán A.
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S114-23. PubMed ID: 27521307
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy in polycythemia vera.
    Stecher G, Reinhardt G.
    Acta Genet Med Gemellol (Roma); 1968 Jan; 17(1):292-302. PubMed ID: 5241850
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Novel Therapies in Polycythemia Vera.
    Tremblay D, Mascarenhas J.
    Curr Hematol Malig Rep; 2020 Apr; 15(2):133-140. PubMed ID: 32034662
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A contemporary approach to the diagnosis and management of polycythemia vera.
    Tefferi A.
    Curr Hematol Rep; 2003 May; 2(3):237-41. PubMed ID: 12901345
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.